210245-80-0
210245-80-0 結(jié)構(gòu)式
基本信息
Zonampanel (YM 872)
7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-1(2H)-quinoxalineacetic acid
1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-
1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dihydro-
(2,3-Dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl)acetic acid monohydrate
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-15072 | Zonampanel | 210245-80-0 | 1 mg | 2000元 |
| 2025/02/08 | HY-15072 | YM 872 Zonampanel | 210245-80-0 | 5mg | 5000元 |
| 2024/08/19 | HY-15072 | YM 872 Zonampanel | 210245-80-0 | 10mg | 8500元 |
常見問題列表
Zonampanel inhibits the human MRP4-mediated transport of [ 3 H]oestradiol 17-D-glucuronide in a concentration-dependent manner. In contrast, Zonampanel (up to 1000 mM) does not inhibit the human MRP2- or BCRP-mediated transport of [ 3 H]oestradiol 17-D-glucuronide or [ 3 H]methotrexate. Zonampanel inhibits the uptake of typical substrates by Oat1, Oat2, and Oat3 with inhibition constant (K i ) values of 7.02 to 10.4 μM. A time- and saturable concentration-dependent increase in [ 14 C]Zonampanel uptake is observed in these cells [K m values: 13.4 to 53.6 μM].
In in vivo experiments, probenecid and cimetidine decrease intrinsic clearance for both the renal secretion and biliary excretion of Zonampanel.